Human DPPIV/CD26 ELISA Kit

Name: Human DPPIV/CD26 ELISA Kit
SKU: DEIA2831
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma, cell culture supernatants, urine

Species Reactivity

Human

Detection Method

Sandwich ELISA

Intended Use

The Human DPPIV/CD26 ELISA Kit kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human CD26 in serum, plasma, cell culture supernatants and urine.

Contents of Kit

1. CD26 Microplate (Item A)
2. Wash Buffer Concentrate (20x) (Item B)
3. Standards (Item C)
4. Assay Diluent A (Item D)
5. Assay Diluent B (Item E)
6. Detection Antibody CD26 (Item F)
7. HRP-Streptavidin Concentrate (Item G)
8. TMB One-Step Substrate Reagent (Item H)
9. Stop Solution (Item I)

Storage

May be stored for up to 6 months at 2 to 8°C from the date of shipment. Standard (recombinant protein) should be stored at -20°C or -80°C (recommended at -80°C) after reconstitution. Opened Microplate Wells or reagents may be stored for up to 1 month at 2 to 8°C. Return unused wells to the pouch containing desiccant pack, reseal along entire edge.
Note: the kit can be used within one year if the whole kit is stored at -20°C. Avoid repeated freeze-thaw cycles.

Detection Range

25 pg/mL - 8000 pg/mL

Sensitivity

25 pg/mL

General Description

Dipeptidyl Peptidase IV (DPPIV; also known as CD26 and adenosine deaminase (ADA) complexing protein 2) is a serine protease that releases Xaa-Pro dipeptides from the N-terminus of oligo- and polypeptides. It is a type II membrane protein consisting of a small cytoplasmic tail, a transmembrane region, and a large extracellular domain. The extracellular domain contains glycosylation sites, a cysteine-rich region, and the catalytic active site (Ser, Asp and His charge relay system). In the native state, DPPIV is present as a non-covalently linked homodimer on the surface of a variety of cell types. The soluble form is also present in human serum and other body fluids. The form purified from human serum or seminal fluid corresponds to the intact extracellular domain.
DPPIV plays an important role in many physiological and pathological processes. It interacts with ADA and CD45, providing a co-stimulating signal to the CD3/T-cell receptor complex. It cleaves many chemokines with Xaa-Pro at their N-terminus, altering their receptor specificity and biological function. It degrades many peptide hormones, such as glucagon-like peptide-1, shorting their bioactivity. DPPIV inhibitors are being developed to extend their bioactivity and currently being tested in late-stage clinical trials for the treatment of type 2 diabetes. DPPIV truncates the N-terminus of procalcitonin, a marker for systemic bacterial and fungal infections. DPPIV interacts with HIV-1 Tat protein and its binding to ADA is inhibited by HIV envelop protein gp120.

Citations

Have you cited DEIA2831 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

The Relationship Between Plasma DPP4 Activity to BDNF Ratio and Mild Cognitive Impairment in Elderly Population With Normal Glucose Tolerance

FRONTIERS IN AGING NEUROSCIENCE

Authors: Xiao, Liuping; Ge, Bo; Chen, Xu; Chen, Bo; Qin, Linyuan; Hu, Xueping; Pan, Haidong; Chen, Yujie; Tian, Li; Gao, Yun; Zheng, Tianpeng

Abstract

Objective: Since decreased brain-derived neurotrophic factor (BDNF) and increased dipeptidyl peptidase-4 (DPP4) activity have both been implicated in the pathogenesis of mild cognitive impairment (MCI), the aim of our study was to evaluate the association of MCI with plasma DPP4 activity to BDNF ratio (DBR) in an elderly population with normal glucose tolerance. Methods: We cross-sectionally measured C-reactive protein, interleukin-6, nitrotyrosine, 8-iso-PGF2a, DPP4 activity BDNF and calculated the DBR in a total of 1,066 elderly participants in China. MCI was determined by the Montreal Cognitive Assessment and finally confirmed by neurologists. Results: An inverse correlation was found between DPP4 activity and BDNF (r = -0.456, P < 0.001) and this inverse correlation was partly mediated by nitrotyrosine and 8-iso-PGF2a. Across rising quartiles of DBR, nitrotyrosine, 8-iso-PGF2a, C-reactive protein and interleukin-6 progressively increased, whereas the Montreal Cognitive Assessment score progressively decreased. Subjects in the lowest quartile of BDNF and highest quartiles of DBR and DPP4 activity, had higher MCI risk compared with subjects in the highest quartile of the BDNF and lowest quartiles of DBR and DPP4 activity, respectively (all P < 0.05). The odds ratio for MCI became more pronounced with decreased BDNF and increased DPP4. Conclusion: In conclusion, a negative correlation was found between DPP4 activity and BDNF, and this negative correlation was partly mediated by oxidative stress, not inflammation. The DBR was positively associated with MCI and thus may be used as a novel risk biomarker for MCI in an elderly population with normal glucose tolerance.

Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia

SAUDI PHARMACEUTICAL JOURNAL

Authors: Al-Rubeaan, Khalid; Bana, Faisal A.; Alruwaily, Fayez G.; Sheshah, Eman; Alnaqeb, Dhekra; AlQahtani, Awad M.; Ewais, Diaa; Al Juhani, Nassr; Hassan, Abdul-hameed; Youssef, Amira M.

Abstract

Objectives: The DISCOVER study is a global, prospective, three- year- observational (non-interventional) study that was conducted in 37 countries throughout the world including Saudi Arabia and aimed to assess variations in treatment patterns and therapeutic outcomes in type 2 diabetic patients. The current manuscript is reporting data of DISCOVER study across different health sectors of various provinces in the Kingdom of Saudi Arabia. Methods: In this study, 519 Saudi type 2 diabetics, non-insulin users, aged 18 years or older, initiating second line therapy, were selected from nine health institutes, in four out of five provinces in Saudi Arabia. Data was collected at baseline (initiation of 2nd line therapy) by the treating physician using an electronic case report form (eCRF) via a web-based data capture system. Each selected subject was asked to complete four self-administered questionnaires. Results: The mean age of the studied population was 52.4 +/- 11 years. Among the subjects selected from the nine medical centers, 55% were men, with almost 65% between the ages of 46 and 65 years. The oral agent used as 1st line in the majority of patients was metformin, prescribed in 89.2% of the study cohort. In the second line, sitagliptin was the most frequently used, at 61.8%. followed by gliclazide, gliben-clamide, and glimepiride at 35.6%, 13.1%, and 12.7%, respectively. Conclusion: Metformin, with or without sulfonylureas, is the most commonly prescribed first-line treatment for patients with type 2 diabetes, managed either in governmental institutions, or in the private sector. The most common second line drugs were DPP4 inhibitors, mainly sitagliptin, followed by the third and second generation of sulfonylureas. Drug affordability was not an issue, since the vast majority of the patients received medication free of charge. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.